Clinical Trial Update: The Effect Of Fragmin In The Treatment Of Neuroischaemic Foot Ulcers In Diabetic Patients (A6301086) [Phase 2, Phase 3]

View source ↗

Summary

Pfizer conducted a Phase 2/Phase 3 trial (A6301086) of Fragmin (dalteparin) for treating neuroischemic foot ulcers in people with diabetes; results were posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Foot Ulcer
• Neuroischemic Foot Ulcer

Drugs mentioned

• FRAGMIN (DALTEPARIN SODIUM)

Snippet

Sponsor: Pfizer | Conditions: Diabetic Foot Ulcer | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2012-01-13